Concepedia

Michael H. Brave

MH

12

Publications

1.1K

Citations

12

H-Index

2006

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

Center for Devices and Radiological Health

Michael H. Brave is an author at United States Food and Drug Administration specializing in pharmacotherapy, urology, and clinical trials.

ORCID

Top concepts

Publications per year

2006–2024

12

Publications

12

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 336 citations

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 239 citations

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors

Jaleh Fallah, Michael H. Brave, Chana Weinstock et al. · Clinical Cancer Research · 2022 · 149 citations · Full text

, , +21

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

Michael H. Brave, Ann T. Farrell, Sue Ching Lin et al. · Oncology · 2010 · 140 citations

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Harpreet Singh, Michael H. Brave, Julia A. Beaver et al. · Clinical Cancer Research · 2016 · 51 citations

, , +15

Rows per page

1–5 of 12